BioSpace News Archive

Revolution Medicines, Inc., today announced that preliminary data from the company’s Phase 1 clinical trial (RMC-4630-01) of RMC-4630 were reported in podium and poster presentations at the 6th AACR-IASLC International Joint Conference: Lung Cancer Translational Science

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) today announced 2020 milestones for IPI-549, a first-in-class, oral, immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition and provided financial guidance for 2020.

BioNTech SE, announced that the Supervisory Board has appointed Ryan Richardson to the Management Board as Chief Strategy Officer and Managing Director.

Industry’s Most Advanced Cloud-Based Clinical Data Aggregation and Enrichment Repository

Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB, has been granted Orphan Drug Designation1 by the US Food and Drug Administration for avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia.

Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Molly White as Vice President, Medical Communications and Advocacy.

Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the appointment of Scott Holmes, M.S./MBA, as Chief Financial Officer

Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials

Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group and Apotex, Inc., together with its US subsidiary, ApoPharma USA Inc., an innovative drug company, active in the hematology and neurodegeneration therapeutic areas, announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox®.

SELLAS Life Sciences Group, Inc. highlighted its clinical development progress for galinpepimut-S and nelipepimut-S and outlined expected milestones for 2020.